Filter By Category
Archives
Share on -
APABETALONE
Generic Name: APABETALONE
ABSTRACT -
Apabetalone is an oral bromodomain and extraterminal domain (BET) inhibitor with relative selectivity for the second bromodomain of BET proteins.
It has been investigated for cardiovascular, metabolic, kidney, and inflammatory diseases by altering transcriptional programs linked to inflammation and atherosclerosis.
It is investigational and not approved for routine clinical use.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Clinical studies have evaluated oral dosing, often twice daily, according to protocol.
- No approved standard dose is established.
- Monitor liver enzymes and other protocol-specified laboratory parameters.
SIDE EFFECTS–
- Possible side effects may include:
- Elevated liver enzymes
- Nausea
- Diarrhea
- Headache
- Nasopharyngitis
- Fatigue
- Dyspepsia
- Potential drug-related hepatic effects
ALLRGIC REACTIONS–
- Hypersensitivity to the active compound or excipients is possible.
- Symptoms may include skin rash, urticaria, pruritus, facial swelling, wheezing, dizziness, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Caution with hepatotoxic drugs or heavy alcohol use.
- Review CYP-mediated interactions and statin or cardiovascular co-medication use.
- Concomitant investigational therapies should follow protocol.
PREAUTIONS–
- Check baseline liver function and monitor transaminases.
- Use caution in significant hepatic impairment.
- Avoid pregnancy due to insufficient reproductive safety data.
- Assess cardiovascular and renal comorbidities before use.
WARNINGS –
- Not approved for general clinical use.
- Potential liver enzyme elevation requires monitoring.
- Use only under trial or specialist supervision.
Share on -
. Developed by